AstraZeneca and Cambridge allies identify cancer breakthrough
Global pharma giant AstraZeneca is working with scientists at a fertile Cambridge University laboratory to commercialise potential new cancer treatments arising from critical research into the ATM protein.
Scientists in Professor Steve Jackson’s laboratory at The Gurdon Institute have identified mechanisms by which drug sensitivities characteristic of ATM-deficient cells can be counteracted by changes in other genes.
These results are important for both understanding cancer drug resistance in the context of sporadic cancers, as well as highlighting potential therapeutic targets for the genetic disease, ataxia-telangiectasia (A-T).
Mutations in the ATM gene cause devastating neurodegenerative and A-T and are also associated with various forms of sporadic cancer.
Previous work has shown that the ATM protein, which is produced from the ATM gene, serves as a molecular guardian of the genome by detecting DNA damage and promoting its repair. Consequently, A-T patients and ATM-deficient cells are hyper-sensitive to various endogenous DNA lesions that can lead to neurodegeneration, as well as DNA-damaging agents used in cancer therapy such as PARP inhibitors.
Professor Jackson said: “This study marks a major step forward in our understanding of how the ATM protein maintains genome stability and how ATM defects can cause cancer and neurodegeneration in human patients with A-T.
“My colleagues and I are very excited by the potential clinical applications for our findings, which we now plan to actively pursue in my laboratory and with our colleagues elsewhere."
Researchers in the lab have collaborated with colleagues at AstraZeneca to identify mechanisms by which the drug sensitivities of ATM-deficient cells can be alleviated by changes in other genes.
Through using cutting-edge CRISPR-Cas9 genetic screens, the authors show that defects in the products of several genes also involved in DNA repair pathways, including components of the BRCA1-A complex and the non-homologous end joining factors LIG4, XRCC4 and XLF, can alleviate the hypersensitivity of ATM-deficient cells to PARP inhibitors and the chemotherapeutic drug topotecan.
As well as providing new mechanistic insights into how cells respond to DNA damage, these findings also have potential medical relevance. First, they suggest how cancers with ATM mutations might evolve resistance in the clinic and how this may make these resistant cancers susceptible to other anti-cancer agents. Second, they suggest potential therapeutic targets for A-T.
Dr Gabriel Balmus from Dementia Research Institute at University of Cambridge, and Domenic Pilger, Jackson Lab Cancer Research UK graduate student, who are co-lead authors on the paper said: “We are excited by the publication of our research and by the possibility that it might improve cancer therapies and could lead to a therapeutic approach for the neurodegenerative disease A-T.”
Dr Josep Forment, Oncology team leader at AstraZeneca who is co-lead and co-corresponding author of the study added: “It has been wonderful collaborating with the group of Prof Steve Jackson to carry out these exciting studies.
“My colleagues and I at AstraZeneca are now exploring how these findings might lead to the discovery of more effective cancer treatments.”
• PHOTOGRAPH SHOWS: Professor Steve Jackson